search
Back to results

Long Term Nitric Oxide Bioavailability on Vascular Health in Chronic Obstructive Pulmonary Disease (COPD-LT)

Primary Purpose

Chronic Obstructive Pulmonary Disease (COPD)

Status
Completed
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
Tetrahydrobiopterin (BH4)
Antioxidant Cocktail
Sponsored by
Augusta University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Chronic Obstructive Pulmonary Disease (COPD) focused on measuring Flow-Mediated Dilation, Kuvan, Antioxidant, FEV1

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • patients with medically diagnosed COPD
  • apparently healthy controls

Exclusion Criteria:

  • FEV1/FVC >0.7 (normal lung function in patients only)
  • Clinical diagnosis of heart disease or diabetes
  • Vasoactive medications (i.e. nitrates, beta-blockers, Viagra etc.)
  • uncontrolled high blood pressure
  • high blood pressure in your lungs
  • thyroid problems
  • Fluid in the lungs
  • Sleep apnea
  • Anemia
  • Raynaud's Phenomenon
  • GI bleeding
  • Gangrene of the digits
  • History of low platelets or coagulopathies
  • Phenylketonuria (PKU)
  • Any allergy to Kuvan

Sites / Locations

  • Georgia Prevention Institute

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Experimental

Arm Label

Tetrahydrobiopterin (BH4)

Antioxidant Cocktail

Arm Description

Blood samples, flow-mediated dilation, arterial stiffness, lung function, and microvascular function will be performed at baseline and 12 weeks following 5mg/kg of Kuvan® or sapropterin dihydrochloride which is a synthetic preparation of the dihydrochloride salt of naturally occurring tetrahydrobiopterin (BH4), taken once a day.

Blood samples, flow-mediated dilation, arterial stiffness, lung function, and microvascular function will be performed at baseline and 12 weeks following an anti-oxidant cocktail (vitamin C 1000 mg, vitamin E 400 IU, and alpha lipoic acid 600 mg) taken once a day.

Outcomes

Primary Outcome Measures

Change in Flow Mediated Dilation
Brachial artery FMD induced by reactive hyperemia assessed vascular endothelial function at baseline and 12 weeks after treatment.

Secondary Outcome Measures

Change in PWV (Pulse Wave Velocity)
Change in pulse wave velocity (carotid to femoral) as measured using tonometry with the Sphygmocor Xcel system at baseline and after 12 weeks of treatment.
FEV1 %Predicted
Forced Expiratory Volume in 1 second. Pulmonary Function Test (PFT).
Percent of ACH to Heat Max
The laser imaging camera is a special camera that shines a low energy laser light on the surface of the skin to measure blood flow. The FLPI makes graphs, photos, and movies of skin blood flow. Acetylcholine is a vasoactive substance that will be used to increase skin blood flow. This variable is the percent of dilation caused by acetylcholine out of the max dilation cause by the warm water bath (44 C).

Full Information

First Posted
May 11, 2016
Last Updated
February 5, 2021
Sponsor
Augusta University
search

1. Study Identification

Unique Protocol Identification Number
NCT02774226
Brief Title
Long Term Nitric Oxide Bioavailability on Vascular Health in Chronic Obstructive Pulmonary Disease
Acronym
COPD-LT
Official Title
Long Term Nitric Oxide Bioavailability on Vascular Health in Chronic Obstructive Pulmonary Disease
Study Type
Interventional

2. Study Status

Record Verification Date
February 2021
Overall Recruitment Status
Completed
Study Start Date
September 2015 (undefined)
Primary Completion Date
July 30, 2018 (Actual)
Study Completion Date
July 30, 2018 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Augusta University

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Chronic obstructive pulmonary disease (COPD) affects up to 14 million people and is among the top five leading causes of death worldwide. Although COPD is a disease of the lungs, recent evidence indicates that COPD is associated with multiple systemic consequences including vascular endothelial dysfunction. Recently, it has been suggested that more patients with COPD die from cardiovascular disease and coronary heart disease than of direct pulmonary complications. Examination of the mechanisms that contribute to a reduction nitric oxide (NO) bioavailability resulting in vascular endothelial dysfunction in patients with COPD are important as endothelial dysfunction has been indicated to be an independent predictor of future atherosclerotic cardiovascular disease and events.
Detailed Description
Researchers have found a link between chronic obstructive pulmonary disease (COPD) and heart disease; however, a link is all they have found. In a previously funded grant, using a double blind, randomized experimental design, the investigators explored the effect of an acute dose of Kuvan or an antioxidant cocktail (1000mg of vitamin C, 600IU of vitamin E, and 600mg alpha-lipoic acid) on vascular health in patients with COPD. Consequently, the investigators found in separate experiments, that a single dose of both antioxidants and Kuvan transiently improves vascular health in patients with COPD. The current project is an attempt to expand on the investigator's previous findings and explore the effects of sub-chronic use of antioxidants and Kuvan on sustaining the improvements in vascular health in COPD.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Chronic Obstructive Pulmonary Disease (COPD)
Keywords
Flow-Mediated Dilation, Kuvan, Antioxidant, FEV1

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
15 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Tetrahydrobiopterin (BH4)
Arm Type
Experimental
Arm Description
Blood samples, flow-mediated dilation, arterial stiffness, lung function, and microvascular function will be performed at baseline and 12 weeks following 5mg/kg of Kuvan® or sapropterin dihydrochloride which is a synthetic preparation of the dihydrochloride salt of naturally occurring tetrahydrobiopterin (BH4), taken once a day.
Arm Title
Antioxidant Cocktail
Arm Type
Experimental
Arm Description
Blood samples, flow-mediated dilation, arterial stiffness, lung function, and microvascular function will be performed at baseline and 12 weeks following an anti-oxidant cocktail (vitamin C 1000 mg, vitamin E 400 IU, and alpha lipoic acid 600 mg) taken once a day.
Intervention Type
Drug
Intervention Name(s)
Tetrahydrobiopterin (BH4)
Other Intervention Name(s)
Kuvan (Sapropterin Dihydrochloride)
Intervention Description
12 week intervention
Intervention Type
Dietary Supplement
Intervention Name(s)
Antioxidant Cocktail
Other Intervention Name(s)
Vitamin C, Vitamin E, Alpha Lipoic Acid
Intervention Description
12 week intervention
Primary Outcome Measure Information:
Title
Change in Flow Mediated Dilation
Description
Brachial artery FMD induced by reactive hyperemia assessed vascular endothelial function at baseline and 12 weeks after treatment.
Time Frame
Change from Baseline and 12 weeks
Secondary Outcome Measure Information:
Title
Change in PWV (Pulse Wave Velocity)
Description
Change in pulse wave velocity (carotid to femoral) as measured using tonometry with the Sphygmocor Xcel system at baseline and after 12 weeks of treatment.
Time Frame
Change from Baseline and 12 weeks
Title
FEV1 %Predicted
Description
Forced Expiratory Volume in 1 second. Pulmonary Function Test (PFT).
Time Frame
Change from Baseline and 12 weeks
Title
Percent of ACH to Heat Max
Description
The laser imaging camera is a special camera that shines a low energy laser light on the surface of the skin to measure blood flow. The FLPI makes graphs, photos, and movies of skin blood flow. Acetylcholine is a vasoactive substance that will be used to increase skin blood flow. This variable is the percent of dilation caused by acetylcholine out of the max dilation cause by the warm water bath (44 C).
Time Frame
Change from Baseline and 12 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: patients with medically diagnosed COPD apparently healthy controls Exclusion Criteria: FEV1/FVC >0.7 (normal lung function in patients only) Clinical diagnosis of heart disease or diabetes Vasoactive medications (i.e. nitrates, beta-blockers, Viagra etc.) uncontrolled high blood pressure high blood pressure in your lungs thyroid problems Fluid in the lungs Sleep apnea Anemia Raynaud's Phenomenon GI bleeding Gangrene of the digits History of low platelets or coagulopathies Phenylketonuria (PKU) Any allergy to Kuvan
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Ryan Harris, Ph.D
Organizational Affiliation
Augusta University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Georgia Prevention Institute
City
Augusta
State/Province
Georgia
ZIP/Postal Code
30912
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
Yes

Learn more about this trial

Long Term Nitric Oxide Bioavailability on Vascular Health in Chronic Obstructive Pulmonary Disease

We'll reach out to this number within 24 hrs